title: Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment.
abstract: Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiological syndrome characterized by acute hypertension, headache, decreased level of consciousness, visual disturbances and seizures associated with characteristic neuroimaging changes indicative of vasogenic edema of the posterior cerebral white matter. Several medical conditions have been associated with PRES including hypertensive encephalopathy and eclampsia. The use of cytotoxic and immunosuppressant drugs, such as those which target vascular endothelial growth factor (VEGF), have also been implicated. We report here the case of a 71-year-old woman with metastatic clear cell renal carcinoma who developed PRES 3 months after commencing sorafenib. Elevated blood pressure (BP) was recorded, and MRI of the brain) of the brain showed asymmetric areas of increased signal intensity within the supratentorial white matter suggestive of PRES. Clinical and radiological features rapidly improved with BP control and discontinuation of sorafenib. Sorafenib was resumed with no sign of PRES recurrence. The present case report supports the hypothesis that, in selected patients, the re-introduction of anti-VEGF therapies after PRES is feasible.
authors: Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium.
authors: Marie
authors: M
authors: Laruelle
authors: Bertrand
authors: B
authors: Filleul
authors: Thierry
authors: T
authors: Duprez
authors: Jean-Pascal
authors: JP
authors: Machiels
mesh_terms: D000368:Aged; D001794:Blood Pressure; D001921:Brain / Q000000981:diagnostic imaging; D002292:Carcinoma, Renal Cell / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000473:pathology; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000150:complications* / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*; D000077157:Sorafenib / Q000009:adverse effects* / Q000627:therapeutic use; D013927:Thrombosis / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D007166:Immunosuppressive Agents; D042461:Vascular Endothelial Growth Factor A; D000077157:Sorafenib
keywords: Anti-VEGF therapies; Neurological toxicity; Posterior reversible encephalopathy syndrome; Renal carcinoma; Sorafenib